2021
Thromboembolic events following cardioversion of acute atrial fibrillation and flutter: a systematic review and meta-analysis
Wong BM, Perry JJ, Cheng W, Zheng B, Guo K, Taljaard M, Skanes AC, Stiell IG. Thromboembolic events following cardioversion of acute atrial fibrillation and flutter: a systematic review and meta-analysis. Canadian Journal Of Emergency Medicine 2021, 23: 500-511. PMID: 33715143, DOI: 10.1007/s43678-021-00103-0.Peer-Reviewed Original ResearchConceptsOral anticoagulation useAcute atrial fibrillationAnticoagulation useThromboembolic eventsAtrial fibrillationThromboembolic riskFlutter patientsInsufficient evidencePrimary analysisSecondary analysisDerSimonian-Laird random-effects modelSafety of cardioversionPrognostic Studies toolRisk of biasRandom-effects modelBackgroundRecent studiesInclusion criteriaMAIN OUTCOMELower riskFibrillationSystematic reviewEvent ratesCardioversionMore studiesPatients
2020
Patterns of oral anticoagulation use with cardioversion in clinical practice
Geurink K, Holmes D, Ezekowitz MD, Pieper K, Fonarow G, Kowey PR, Reiffel JA, Singer DE, Freeman J, Gersh BJ, Mahaffey KW, Hylek EM, Naccarelli G, Piccini JP, Peterson ED, Pokorney SD. Patterns of oral anticoagulation use with cardioversion in clinical practice. Heart 2020, 107: 642-649. PMID: 32591363, DOI: 10.1136/heartjnl-2019-316315.Peer-Reviewed Original ResearchConceptsStroke/transient ischemic attackVitamin K antagonistsNovel oral anticoagulantsTransient ischemic attackTransoesophageal echocardiogramAtrial fibrillationClinical practiceAtrial Fibrillation IIOral anticoagulation useTime of cardioversionBetter Informed TreatmentMonths of enrollmentIncidence of deathLow-risk procedureSimilar ratesAnticoagulation useIschemic attackMajor bleedingK antagonistsOral anticoagulantsClinical outcomesOutcomes RegistryCardiovascular hospitalisationAF diagnosisInclusion criteria
This site is protected by hCaptcha and its Privacy Policy and Terms of Service apply